Wednesday, 30 September 2015
The New England Journal of Medicine (NEJM) has published positive results from two pivotal, multi-centre, Phase III studies –AMAGINE-2 and AMAGINE-3 – demonstrating that treatment with brodalumab resulted in significant clinical improvements in patients with moderate to severe psoriasis and was superior to both placebo and ustekinumab, a leading approved treatment for psoriasis.
Detailed results and safety information as published in NEJM can be viewed here.
Bing Yao, Senior Vice President, Research and Development and Head of the Respiratory, Inflammation & Autoimmunity Innovative Medicines unit at MedImmune, AstraZeneca’s global biologics research and development arm, said: “Publication of these data in NEJM underscores the importance of brodalumab as a potential new treatment for people with psoriasis, a serious, chronic disease that can have an overwhelming, negative impact on patients’ lives. We look forward to progressing this novel molecule to regulatory submissions in the near future.”
Brodalumab, a fully human monoclonal antibody, is the only investigational treatment in development that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 cytokines (A, F, A/F and C) to the receptor. Previous results reported from the two studies can be viewed here: AMAGINE-2 and AMAGINE-3.
The studies were funded by AstraZeneca and Amgen, the former sponsor of the brodalumab programme. AstraZeneca recently announced it has entered into a collaboration with Valeant Pharmaceuticals, granting Valeant an exclusive license to develop and commercialise brodalumab. Regulatory submissions in the United States and European Union for brodalumab in moderate to severe psoriasis are planned for the fourth quarter of 2015.
NOTES FOR EDITORS
About Psoriasis
Psoriasis is a serious, chronic inflammatory disease that causes raised, red, scaly patches to appear on the skin, typically affecting the outside of the elbows, knees or scalp, though it can appear on any location. Approximately 125 million people worldwide have psoriasis, and 80 percent of those patients have plaque psoriasis.
About Brodalumab
Brodalumab is a novel, fully human monoclonal antibody that binds to the interleukin-17 (IL-17) receptor and inhibits inflammatory signaling by blocking the binding of several IL-17 ligands to the receptor. By stopping IL-17 ligands from activating the receptor, brodalumab prevents the body from receiving signals that may lead to inflammation. The IL-17 pathway plays a central role in inducing and promoting inflammatory disease processes.
About AstraZeneca
AstraZeneca is a global, innovation-driven biopharmaceutical business that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection and neuroscience diseases. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com
CONTACTS
| Media Enquiries | ||
|---|---|---|
| Esra Erkal-Paler | (UK/Global) | +44 20 7604 8030 |
| Vanessa Rhodes | (UK/Global) | +44 20 7604 8037 |
| Ayesha Bharmal | (UK/Global) | +44 20 7604 8034 |
| Jacob Lund | (Sweden) | +46 8 553 260 20 |
| Michele Meixell | (US) | +1 302 885 6351 |
| Investor Enquiries UK | ||
|---|---|---|
| Thomas Kudsk Larsen | +44 20 7604 8199 | mob: +44 7818 524185 |
Eugenia Litz (Respiratory, Inflammation and Autoimmunity) |
+44 20 7604 8233 | mob: +44 7884 735627 |
Nick Stone (Cardiovascular and Metabolic Disease) |
+44 17 6326 3994 | mob: +44 7717 618834 |
| Craig Marks | +44 20 7604 8591 | mob: +44 7881 615764 |
Christer Gruvris (Infection, Neuroscience and Gastrointestinal Disease) |
+44 20 7604 8126 | mob: +44 7827 836825 |
| Investor Enquiries US | ||
|---|---|---|
| Lindsey Trickett | +1 301 398 5118 |
mob: +1 240 543 7970 |
Mitch Chan (Oncology / Respriratory, Inflammation and Autoimmunity) |
+1 301 398 1849 | mob: +1 301 398 1849 |
| Dial / Toll-Free | +1 301 398 3251 |
mob: +1 866 381 7277 |